Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Cancer Research
Antonio JimenoManuel Hidalgo

Abstract

The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall activity is minimal, and known predictive factors for EGFR inhibitor efficacy are infrequent in this disease. We tested the hypothesis that global activation of the EGFR pathway is predictive of EGFR inhibitor efficacy. Pancreatic cancer tumors directly xenografted at surgery were treated with the EGFR inhibitors erlotinib and cetuximab and analyzed for biological features. Two of 10 tumors were sensitive, and by global gene expression profiling with gene set enrichment analysis, the EGFR pathway was highly expressed in sensitive compared with resistant tumors. The core gene components driving EGFR pathway overexpression were pathway ligands and positive effectors. In a prospective validation, the EGFR pathway-based signature correctly predicted anti-EGFR treatment response in eight additional tumors and was not predictive of response to gemcitabine and CI1040 (a MEK inhibitor). Analysis of EGFR, KRAS, and PIK3CA mutations and gene amplification by fluorescence in situ hybridization and multiplex ligation-dependent probe amplification showed that none of these genetic abnormalities were neither predicti...Continue Reading

Citations

Jun 7, 2011·Human Genetics·Andrew V Biankin, Thomas J Hudson
Apr 18, 2012·Nature Reviews. Clinical Oncology·John J TentlerS Gail Eckhardt
Jun 27, 2012·Nature Reviews. Gastroenterology & Hepatology·Eithne CostelloJohn P Neoptolemos
Jun 30, 2009·Bioinformatics·David L GoldSong Liu
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria S PinoPaola Nisticò
Aug 19, 2010·Molecular Cancer Therapeutics·Stephen B Keysar, Antonio Jimeno
Jan 5, 2010·Immunotherapy·Zhi-Qiang Huang, Donald J Buchsbaum
Dec 17, 2008·World Journal of Gastroenterology : WJG·Alphonse-E Sirica
Apr 18, 2014·Genome Medicine·Raquel Martinez-GarciaManuel Hidalgo
Apr 15, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M BenavidesE Aranda
Sep 18, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Cristóbal Belda-IniestaJaime Feliú
Feb 18, 2010·Expert Opinion on Drug Discovery·Georg FeldmannAnirban Maitra
Jan 18, 2016·Journal of Comparative Pathology·I AmorimF Gärtner
Jul 2, 2009·International Journal of Cancer. Journal International Du Cancer·Wenjun ChangGuangwen Cao
Sep 25, 2015·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Sayaka SeinoMasaaki Takechi
Jan 14, 2011·The Biochemical Journal·Aneta SwatAngel R Nebreda
Jul 17, 2015·Clinical and Translational Gastroenterology·Juan ZhouThomas D Wang
Sep 15, 2012·Cancer Cell·Christine M ArditoJens T Siveke
Sep 25, 2014·BioMed Research International·Ingrid GarajováElisa Giovannetti
Feb 15, 2016·Clinical Pharmacology and Therapeutics·E IzumchenkoD Sidransky
Jun 5, 2016·Molecular & Cellular Proteomics : MCP·Emily S HumphreyRoger J Daly
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E IzumchenkoD Sidransky
Jul 29, 2010·British Journal of Cancer·I Garrido-LagunaM Hidalgo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.